Protagenic Therapeutics, Inc.
PTIX
$0.49
$0.000.00%
OTC PK
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 12/31/2024 | ||
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | |
| Total Other Revenue | -- | -- | -- | -- | |
| Total Revenue | -- | -- | -- | -- | |
| Cost of Revenue | -- | -- | -- | -- | |
| Gross Profit | -- | -- | -- | -- | |
| SG&A Expenses | 771.30K | 840.60K | 814.30K | 266.80K | |
| Depreciation & Amortization | -- | -- | -- | -- | |
| Other Operating Expenses | -- | -- | -- | -- | |
| Total Operating Expenses | 925.10K | 1.11M | 1.21M | 401.40K | |
| Operating Income | -925.10K | -1.11M | -1.21M | -401.40K | |
| Income Before Tax | 2.21M | -869.50K | -5.06M | -850.30K | |
| Income Tax Expenses | -- | -- | -- | -- | |
| Earnings from Continuing Operations | 2.21M | -869.50K | -5.06M | -850.30K | |
| Earnings from Discontinued Operations | -- | -- | -- | -- | |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | |
| Minority Interest in Earnings | -- | -- | -- | -- | |
| Net Income | 2.21M | -869.50K | -5.06M | -850.30K | |
| EBIT | -925.10K | -1.11M | -1.21M | -401.40K | |
| EBITDA | -912.50K | -1.10M | -1.20M | -- | |
| EPS Basic | 1.14 | -0.47 | -1.37 | -0.16 | |
| Normalized Basic EPS | 0.71 | -0.29 | -0.85 | -0.10 | |
| EPS Diluted | 1.14 | -0.47 | -1.37 | -0.16 | |
| Normalized Diluted EPS | 0.71 | -0.29 | -0.85 | -0.10 | |
| Average Basic Shares Outstanding | 1.93M | 1.85M | 3.70M | 5.40M | |
| Average Diluted Shares Outstanding | 1.93M | 1.85M | 3.70M | 5.40M | |
| Dividend Per Share | -- | -- | -- | -- | |
| Payout Ratio | -- | -- | -- | -- | |